Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of patients with locally advanced esophageal cancer, approximately half of the patients will experience local regional recurrence or distant metastasis. Lymphocytes are crucial immune cells in the human body, playing a key role in combating infections and tumor development. In recent years, an increasing body of research has indicated that lymphocyte depletion is a significant factor associated with poor prognosis in various solid tumors, including esophageal cancer. The lymphocyte depletion caused by radiotherapy has garnered considerable attention from oncologists. However, there is still a lack of prospective clinical research data on lymphocyte protection in thoracic tumors. Therefore, this study aims to provide high-level evidence from evidence-based medicine regarding the correlation between lymphocyte depletion and prognosis in esophageal cancer patients, offering more effective strategies and methods to improve the outcomes of neoadjuvant chemoradiotherapy for esophageal cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chętny do udziału w badaniu i podpisanie zgody
- •Potwierdzony rozpoznaniem nowotworu przełyku
- •Zaawansowany lokalnie nowotwór przełyku
- •Wiek od 18 do 80 lat
- •Dobry stan ogólny (wynik KPS powyżej 80)
✗ Disqualifies
- •Nowotwór przełyku z przerzutami do odległych narządów
- •Brak zgody na chemioterapię
- •Przerzuty do opłucnej lub płyn w opłucnej
- •Ciąża lub karmienie piersią
- •Poważne inne choroby uniemożliwiające radioterapię
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Ruijin hospital, Shanghai jiaotong university school of medicine
Shanghai, China
Trial contact
Wei-Xiang Qi, Dr.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.